TNI BioTech, Inc. (TNIB: OTCQB) | TNI BioTech, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TNI BioTech, Inc. (TNIB: OTCQB) | TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203

 

TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203 [SG1]  

 

Bethesda MD June 7, 2013 .  TNI BioTech, Inc. (OTC:TNIB) the ?Company? announced today that effective as of the opening of business on Monday June 10, 2013, the Company will require the mandatory exchange of all existing common stock certificates issued with or under any prior CUSIP number for new stock certificates with the new CUSIP number 872608203. 

 

The mandatory share certificate exchange is to resolve issues affecting the settlement of trades in its common stock, provide clarity and uniformity in the market place and to ensure the security of all legitimate shareholders of the Company.  Subsequent to the mandatory share certificate exchange, the management of the Company anticipates that any confusion or inconsistency with the processing of certificates by brokers or clearing agents should be resolved.

 

The correct & current CUSIP number 872608203 was issued by the S&P CUSIP division on May 28, 2013 and has been communicated to the marketplace today, Friday, June 7, 2013.

 

The Company hereby requires that all persons, corporations and/or other legal entities in possession of stock certificates bearing the original CUSIP numbers in the original names of Galliano International Ltd. (363816109), Resorts Clubs International, Inc. (761163-104/203/302), pH Environmental Inc (69338E107) and TNI BioTech, Inc. (872608104) must tender these certificates immediately to the Company`s stock transfer agent Direct Transfer LLC to exchange for certificates depicting the name TNI BioTech, Inc. and the current CUSIP number 872608203.  All new certificates will be issued with the same legend as the presented certificates.

 

The exchange will be for a 1 for 1, with the stipulation that the old certificates with the old company names, CUSIP numbers and design, will be void, and shall be worthless, non-transferable and non-tradeable in any public or private market or exchange beginning June 10, 2013 and shall have no value except for the right to be exchanged for new certificates.

 

Persons who currently hold their shares in brokerage accounts or ?street name? are required to present their common stock certificates if still in certificated form.  To complete this mandatory exchange, shareholders must surrender or direct their broker to surrender their old stock certificate(s) to the Company?s transfer agent, ?Direct Transfer LLC.  Direct Transfer LLC?s contact information is:

 

Direct Transfer LLC

500 Perimeter Park Drive Suite D

Morrisville, North Carolina 27560

 

Upon receipt of the old certificate, the transfer agent will issue to holders a new certificate with the same number of shares but bearing the name TNI BioTech, Inc. with the updated CUSIP number.

 

Stockholders will not receive new stock certificates until they have turned in their old stock certificates to the transfer agent.  TNI BioTech, Inc. will cover the fee for issuing the new certificates. As a result of the stock certificate exchange, all trades in the Company?s common stock made after the close of business on June 7, 2013, can be delivered only with stock evidenced by certificates bearing the name TNI BioTech, Inc. with new CUSIP number 872608203, as the old CUSIP number will cease to be eligible for trading.

 

For further details, please call or email Direct Transfer LLC at (919) 481-4000 or transfer@issuerdirect.com.

 

 

 

About TNI BioTech, Inc.

 

TNI BioTech, Inc., is a biotech company working to combat chronic, life-threatening diseases through the activation modulating the body?s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

 

Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical program involves immunotherapy with met-enkephalin (MENK) and/or opioid growth factor (OGF), which has been shown to stimulate the immune system even in patients with advanced cancer. Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for low dose naltrexone and/or MENK as valuable candidates in the treatment of the following: 

?        Autoimmune states such as rheumatoid arthritis and multiple sclerosis;

?        As an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery;

?        As an adjunct to antibiotics in the treatment of a variety of infectious diseases, including: patients with AIDS, in combination with retroviral drug therapy

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company?s expectations or beliefs concerning future events. Statements containing expressions such as ?believes,? ?anticipates,? ?intends,? or ?expects,? used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

 

 

See http://www.tnibiotech.com for more information.

 

Contact: Global Investment Media

Phone:  310-353-6277

 

 

 

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Marjorie Taylor Greene's Diverse Portfolio Emphasizes Growth

Updated Category News Views 243

Marjorie Taylor Greene's Investment Choices Marjorie Taylor Greene, a well-known congressional representative, is making headlines lately with her recent stock investments. Reports indicate that her investment decisions reflect a strong interest in diverse sectors, including technology, healthcare, and logistics. This varied approach highlights her strategic thinking as...

Continue Reading
RBB Bancorp's Incredible Third Quarter Gains and Dividend

Updated Category News Views 178

RBB Bancorp: A Review of Stellar Financial Performance RBB Bancorp, alongside its subsidiaries, has recently announced impressive financial results for the quarter ended September 30, 2025. In an era where financial stability is paramount, RBB Bancorp (NASDAQ:RBB) emerged with promising metrics indicating solid progress. Key Financial Highlights for Q3 2025 Net income...

Continue Reading
Hancock Whitney to Share Q3 2024 Results and Insights Soon

Updated Category News Views 69

Exciting News from Hancock Whitney Corporation Hancock Whitney Corporation (Nasdaq: HWC) is about to share its financial performance for the third quarter of 2024. This announcement will take place after the market closes, paving the way for an insightful conference call with both analysts and investors. Details on Financial Results and Conference Call The expected...

Continue Reading
GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales

Updated Category News Views 229

GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales GunsAmerica stands at the forefront of the online firearm marketplace, continually evolving to ensure the utmost safety and security for its users. The platform has earned a stellar reputation over its impressive 28-year history by prioritizing secure firearm transactions and implementing robust measures...

Continue Reading
Acrivon Therapeutics Pushes Ahead with ACR-2316 Trials

Updated Category News Views 70

Exciting Milestone in Oncology Trials Acrivon Therapeutics, Inc. has recently reached a significant milestone by dosing its first patient in the Phase 1 clinical trial of ACR-2316. This innovative WEE1/PKMYT1 inhibitor was developed using Acrivon’s advanced AP3 platform, which accelerates the discovery and design of effective cancer treatments. The progress marks a...

Continue Reading